Clinical trials: Alopecia Areata
Alopecia Areata
Polymorphism of Janus Kinase 1 and 2 (JAK 1&2) in Patients With Alopecia Areata
Introduction Alopecia areata (AA) is a complex inflammatory disease characterized by cellular infiltration of T- lymphocytes targeting hair follicles, disrupting the anagen phase, with spontaneous remission, recurrence, and…
- Trial name
- NCT05861401
- Testing
- Janus Kinase 1 and 2
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Alopecia
Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors
This study is being done to see if the Paxman scalp cooling device can prevent hair loss in pediatric patients receiving chemotherapy for non-cancerous conditions or solid tumors.
- Trial name
- NCT04764357
- Testing
- Paxman Scalp Cooling System, Alopecia Assessments, Patient Reported Outcomes Questionnaires
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Jude Children's Research Hospital
Alopecia Areata
Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata
Alopecia areata is a non-scarring hair loss disorder that affects both sexes equally. Incidence of the disease varies for different populations and in different studies, with global incidence ranging from 0.57% to 3.8%.
- Trial name
- NCT04003376
- Testing
- fractional carbon dioxide laser alone, Triamcinolone Acetonide 10mg/mL, platelet rich plasma
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Acceptance of Visible Chronic Dermatological Disease, Disease Acceptance
Measure of Acceptance of chRonic Visible sKin conditionS
The objective of this protocol is to validate 4 scales for evaluating the acceptance of visible chronic dermatological diseases (port wine stains, alopecia areata, vitiligo, hyperpigmentation...) with a large number of patients…
- Conditions
- Acceptance of Visible Chronic Dermatological Disease, Disease Acceptance, Psychological Well-Being, Social Segregation
- Trial name
- MARKS (NCT06103903)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Tours
Alopecia Areata
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers.
- Trial name
- NCT06562270
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorEvitas
Alopecia Areata
Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata
The purpose of this study is to evaluate the efficacy and tolerability of squaric acid dibutylester (SADBE) in children and adolescents with alopecia areata (AA) and to evaluate effect of squaric acid dibutyl ester on…
- Trial name
- NCT05414266
- Testing
- SADBE 5%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- The University of Texas Health Science Center, Houston
Atopic Dermatitis, Psoriasis
Determinants of Chronic Inflammatory Skin Disease Trajectories
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation…
- Conditions
- Atopic Dermatitis, Psoriasis, Lichen Planus, Alopecia Areata
- Trial name
- NCT05928169
- Testing
- Topical and systemic drugs
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Alopecia Areata
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be…
- Trial name
- NCT06564805
- Testing
- Candida Albicans Antigen Injection
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Androgenetic Alopecia, Hair Loss
Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study
This is a comparative retrospective study of the efficacy of platelet-rich plasma injections and injections with commercial products advertised to promote hair regrowth for patients with androgenetic alopecia.
- Conditions
- Androgenetic Alopecia, Hair Loss, Alopecia
- Trial name
- NCT05129800
- Testing
- Platelet-rich plasma, Mesotherapy
- Volunteers
- 72 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Telogen Effluvium
Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment
This is a randomized, double-blind, controlled clinical trial investigating the efficacy and safety of millet seed extract capsules in treating telogen effluvium in female patients.
- Trial name
- NCT07348120
- Testing
- Millet Seed Extract group, Biotin group
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Kasr El Aini Hospital
Alopecia Areata
Topical Cetirizine in Treatment of Localized Alopecia Areata
Evaluate and compare the efficacy and safety of topical cetirizine 1%, versus topical betamethasone valerate 0.1% in the treatment of localized alopecia areata.
- Trial name
- NCT05803070
- Testing
- Topical Cetirizine 1 %, Topical betamethasone valerate 0.1%
- Volunteers
- 59 people
- Sponsor
- Assiut University
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Alopecia Areata
Childhood Alopecia Areata Study Using the 308-nm Excimer Laser
Alopecia Areata (AA) is a skin restricted autoimmune disease of the hair follicle, resulting in hair loss of the scalp, and in severe cases of the entire body.
- Trial name
- NCT01736007
- Testing
- 308-nm excimer laser to alopecia patch, Liquid light guide tip on laser
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Phoenix Children's Hospital
Alopecia Areata, Alopecia Totalis
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT06278402
- Testing
- Tofacitinib
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Jinnah Hospital
Alopecia Areata(AA), Alopecia Areata (AA)
Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
Rationale: Since the introduction of Janus kinase (JAK) inhibitors, there has been a significant advancement in the treatment of pediatric alopecia areata.
- Conditions
- Alopecia Areata(AA), Alopecia Areata (AA), Alopecia Totalis/Universalis, Alopecia Universalis (AU)
- Trial name
- COMPARE (NCT07381556)
- Testing
- Methotrexate, Cyclosporin (CSA)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Focal Non-cicatricial Alopecia
Relevance of Trichoscopy in Differential Diagnosis of Focal Non-cicatricial Alopecia in Children
Alopecia is a common, distressing condition that is sometimes difficult to diagnose and treat. Losing hair is not usually health threatening; it can scar a young child's vulnerable self-esteem by causing immense psychological and…
- Trial name
- NCT03260777
- Testing
- Trichoscopy
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Alopecia Areata
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
Primary: To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: To evaluate key clinical outcome assessments
- Trial name
- NCT03354637
- Testing
- ATI-50002 high dose, ATI-50002 low dose
- Where
- 23 sites in United States
- Volunteers
- 129 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia Areata
Long-Term PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.
- Trial name
- ALLEGRO-LT (NCT04006457)
- Testing
- PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 1,057 people
- Sponsor
- Pfizer
Alopecia Areata
Topical Garlic Concentrate for Alopecia Areata in Children
Management of pediatric alopecia is particularly challenging given the chronicity of the condition, limited therapeutic response and devastating psychological effects.
- Trial name
- NCT02691117
- Testing
- garlic concentrate
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Elena Pope
Alopecia Areata
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
- Trial name
- NCT07133308
- Testing
- Deuruxolitinib
- Where
- 64 sites in United States, Canada
- Volunteers
- 355 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.